Activated protein C in the treatment of sepsis

Anaesthesia

Volumn 57, Issue 5, 2002, Pages 501-521

  Morris, C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; PLACEBO; PROTEIN C;

BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG HALF LIFE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE COST; HUMAN; INTENSIVE CARE UNIT; LETTER; MEDICAL LITERATURE; MORTALITY; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PROTHROMBIN TIME; SEPSIS; STATISTICAL SIGNIFICANCE; SURVIVAL;

EID: 0036257162     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.2002.26264.x     Document Type: Letter

References (7)

1. Efficacy and safety of recombinant human activated protein C for severe sepsis
2. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
3. An open label study of the role of adjuvant haemostatic support with protein C replacement therapy in purpura fulminans associated meningococcaemia
4. Activated protein C vs. protein C in severe sepsis
5. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
6. Update in thrombolytic therapy
7. Population based cost utility study of interferon beta-1b in secondary multiple sclerosis